Spike Protein News and Research

RSS

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Researchers tested the antibodies elicited from mRNA vaccination and compared them to those from natural SARS-CoV-2 infection. They found the vaccine did not have antibodies to the virus nucleocapsid protein but had potent RBD antibodies.

21 Apr 2021

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Researchers in the United States have shown that an antibody test measuring host reactivity to the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may better detect natural infection among vaccinated individuals than an assay that measures reactivity to the viral spike protein.

21 Apr 2021

Children develop strong, long-lasting immunity following SARS-CoV-2 infection

Researchers in the UK have conducted a study that may explain why children who become infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not generally develop severe coronavirus disease 2019 (COVID-19).

20 Apr 2021

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

A new study shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host cells. This finding could inform their use to treat symptomatic COVID-19.

20 Apr 2021

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

A team of international scientists recently demonstrated that antibodies generated in response to the DNA vaccine INO-4800 can effectively neutralize some of the recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as G614, 501Y.V1, and 501Y.V2.

20 Apr 2021

Study examines SARS-CoV-2 seropositivity in healthy young adults and risk of reinfection

New research has been published in The Lancet Respiratory Medicine, which focuses on evaluating the effect of SARS-CoV-2 seropositivity on the possibility of developing SARS-CoV-2 infection in a young and healthy population. This study is based on the longitudinal prospective cohort study that involves the COVID-19 Health Action Response for Marines (CHARM).

20 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

A small study, previously posted to the medRiv preprint server in early March, was recently published in the journal Science Immunology. The now peer-reviewed research led by E. John Wherry of the University of Pennsylvania Perelman School of Medicine finds people previously exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced a more robust immune response after receiving the first — but not the second mRNA vaccine.

19 Apr 2021

Researchers manufacture the SARS-CoV-2 RBD in pichia

Researchers in the United States and India have developed a high-volume, low-cost platform for manufacturing vaccines to protect against different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

19 Apr 2021

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.

19 Apr 2021

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

A team of scientists in Germany recently evaluated the specificities and sensitivities of different serological assays for detecting antibodies against SARS-CoV-2.

19 Apr 2021

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Two researchers from the Université Libre de Bruxelles in Belgium, Fabrizio Pucci and Marianne Rooman, recently built a simplified computational model, called SpikePro, to predict the SARS-CoV-2 fitness from the amino acid sequence and structure of the spike protein. This study focuses on the spike protein’s stability and the binding affinity to the host receptor.

19 Apr 2021

Plant-derived compound isorhamnetin may have antiviral potential against SARS-CoV-2

The lack of new or repurposed drugs to treat patients with severe or critical COVID-19 has been one of the biggest hurdles to reducing mortality rates in the ongoing pandemic caused by SARS-CoV-2. A new study describes the potential for the use of the plant molecule isorhamnetin in the management of this virus.

19 Apr 2021

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.

19 Apr 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

Supercomputer simulations illuminate the behavior of dominant G form of SARS-CoV-2

Large-scale supercomputer simulations at the atomic level show that the dominant G form variant of the COVID-19-causing virus is more infectious partly because of its greater ability to readily bind to its target host receptor in the body, compared to other variants.

17 Apr 2021

Past COVID-19 infection does not completely protect against reinfection in young people

Although antibodies induced by SARS-CoV-2 infection are largely protective, they do not completely protect against reinfection in young people, as evidenced through a longitudinal, prospective study of more than 3,000 young, healthy members of the US Marines Corps conducted by researchers at the Icahn School of Medicine at Mount Sinai and the Naval Medical Research Center, published April 15 in The Lancet Respiratory Medicine.

17 Apr 2021

Candidate coronavirus vaccines show promising results in early animal testing

A candidate vaccine that could provide protection against the COVID-19 virus and other coronaviruses has shown promising results in early animal testing.

17 Apr 2021

Ask KHN-Politifact: I’ve recovered from Covid. Why do i still have to mask up?

More than 120 million Americans have joined arguably the most sought-after club on Earth: those immunized against the coronavirus.

16 Apr 2021

Spike Protein News and Research

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Children develop strong, long-lasting immunity following SARS-CoV-2 infection

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

Study examines SARS-CoV-2 seropositivity in healthy young adults and risk of reinfection

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

Researchers manufacture the SARS-CoV-2 RBD in pichia

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Plant-derived compound isorhamnetin may have antiviral potential against SARS-CoV-2

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Supercomputer simulations illuminate the behavior of dominant G form of SARS-CoV-2

Past COVID-19 infection does not completely protect against reinfection in young people

Candidate coronavirus vaccines show promising results in early animal testing

Ask KHN-Politifact: I’ve recovered from Covid. Why do i still have to mask up?

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News